Blood-pressure reduction is the only proven treatment to prevent stroke. Whether a single pill that combines three antihypertensive drugs at low doses, in addition to standard antihypertensive ...

The study published in eClinicalMedicine by Huilin Tang and colleagues from the University of Pennsylvania Perelman School of ...

However, emerging research is now raising new questions about their broader effects on men's health. A recent study ...

GLP-1 drugs for diabetes may increase erectile dysfunction risk by 26% versus DPP-4 inhibitors Erectile dysfunction affects ...

A recent study published in the International Journal of Molecular Sciences revealed that patients initiating sodium–glucose ...

New data reveal key differences in antihyperglycaemic agents safety for older adults with Type 2 diabetes. Learn more.

GLP-1 receptor agonist use may be associated with a modest increase in erectile dysfunction (ED) risk in men with type 2 ...

Generic dapagliflozin is indicated to lower heart failure hospitalization risk in type 2 diabetes with established cardiovascular disease or multiple risk factors, and to improve glycemic control ...

Dipeptidyl peptidase-4 inhibitors are widely used for type 2 diabetes because they have a low risk of severe hypoglycemia and are weight neutral, but their relationship with malignancy remains ...

Voluntary pause of the Phase 3 HERO and OLE trials evaluating ARD-101 for the treatment of hyperphagia in individuals with Prader-Willi Syndrome, further guidance on the program expected in Q2 2026 ...

SGLT2 inhibitors showed significantly improved mortality benefits compared with DPP-4 inhibitors in patients with diabetic kidney disease (DKD) in a large target trial emulation study that adds ...